Life sciences software & AI news

Daily news on AI, software, and digital tools for pharma, biotech, CROs, and life sciences research labs.

Showing 1000+ results
A minimalist illustration of a molecule and a computer chip, symbolizing AI in drug discovery.

May 21, 2026

QIAGEN Partners with NVIDIA to Expand AI Drug Discovery

QIAGEN has announced a strategic partnership with NVIDIA to enhance AI-driven drug discovery and biomedical research.This collaboration aims to integrate NVIDIA's advanced computing capabilities and the BioNeMo platform into QIAGEN Digital Insights (QDI). By combining QIAGEN’s extensive biological and bioinformatics resources with NVIDIA's AI technologies, the partnership seeks to improve data analysis, biomarker discovery, and target identification throughout the drug development process.The in
A minimalist representation of a clinical data network node.

May 21, 2026

Century Health: $5 Million Seed Raised For AI-Powered Clinical Data Abstraction Platform

Century Health has successfully raised $5 million in a seed funding round aimed at enhancing its AI-driven clinical data abstraction platform. This round, led by Origin Ventures, also saw participation from InnovateHealth Ventures, 25madison, and other notable investors.The funding will facilitate the expansion of partnerships within the pharmaceutical and life sciences sectors, as well as the growth of Century Health's specialty provider data network. Central to their offerings is the Century H
A minimalist illustration of a smartwatch and a speech bubble representing digital health and social media.

May 21, 2026

AI, Digital Health Expand Drug Safety Monitoring

AI and digital health technologies are poised to enhance drug safety monitoring by leveraging real-world data sources, including social media and wearable devices, to identify medication side effects more swiftly than traditional methods.Recent research highlights the potential of AI and digital tools to transform pharmacovigilance by analyzing vast datasets from social media platforms like Reddit and X. These platforms can reveal patient experiences that often go unreported in clinical trials,
A test tube with a colorful liquid sample in a laboratory setting

May 21, 2026

QIAGEN and NVIDIA partner on AI drug discovery

QIAGEN has announced a strategic partnership with NVIDIA to enhance AI-driven drug discovery through advanced computing and the BioNeMo platform, unveiled at the 2026 BIO-IT World Conference & Expo.This collaboration aims to merge QIAGEN’s extensive biomedical knowledge with cutting-edge artificial intelligence, thereby streamlining processes in drug discovery, target identification, and biomarker research. By leveraging this integration, pharmaceutical and biotechnology researchers will be bett
An enzyme sample on a lab surface in a dimly lit laboratory

May 21, 2026

Imperagen Raises €5.8M Seed for AI and Quantum Enzyme Engineering

Imperagen, a Manchester-based biotech firm, has secured €5.8 million in seed funding to enhance its innovative enzyme engineering platform, which utilizes AI and quantum simulation technologies.Recently, Imperagen announced the closing of a £5 million (~€5.8 million) seed funding round led by PXN Ventures, with participation from existing investors IQ Capital and Northern Gritstone. This funding brings the company's total investment to £8.5 million since its inception in 2021. The new capital wi
A minimalist representation of a golden ticket symbolizing biotech opportunities.

May 21, 2026

Chong Kun Dang backs US biotech scouting with LabCentral partnership - CHOSUNBIZ

Chong Kun Dang Pharmaceutical is enhancing its commitment to biotech innovation through a partnership with LabCentral, focusing on technology discovery for startups.The collaboration aims to foster open innovation in the biotech sector, highlighted by a recent event in Boston where Chong Kun Dang awarded a "golden ticket" to Aphelos Bioscience. This startup, established in 2024, is leveraging AI to develop treatments for autoimmune diseases and possesses expertise in proteins and T-cell biology.
A surgical instrument on a tray in an operating room

May 21, 2026

Laurexa Capital closes €520M fundraising to propel European medtech companies

Lauxera Capital Partners has successfully closed a €520 million fundraising round for its Lauxera Growth II fund, exceeding its initial target and demonstrating strong investor confidence.The firm announced this significant milestone on May 19, highlighting that over 90% of previous investors from its 2021 fundraising returned with increased contributions. The primary objective of this fund is to support the growth of promising European healthtech and medtech companies, particularly by facilitat
AI chip on a workbench with circuit boards

May 21, 2026

Hoth Therapeutics stock (US44133K1097): biotech pivots toward AI chips with Rocket One plan

Hoth Therapeutics is undergoing a significant transformation, rebranding itself as Rocket One and shifting its focus from biotechnology to artificial intelligence accelerator chips. This strategic pivot may have implications for its market position and appeal to investors interested in the intersection of AI hardware and healthcare.Previously known for its work in developing treatments for inflammatory and dermatologic diseases, Hoth Therapeutics aims to leverage its expertise in a new direction
minimalist illustration of a drug compound

May 21, 2026

Concept Life Sciences Partners with OpenBench to Deliver Success-Based Drug Discovery Services for Early-Stage Biotech

Concept Life Sciences has formed a strategic alliance with OpenBench to enhance drug discovery services for early-stage biotech firms through a fee-for-success model.This collaboration integrates OpenBench's AI-driven discovery platform with Concept Life Sciences' expertise in medicinal chemistry and in-vitro screening. The partnership aims to expedite the process from target identification to validated hit series, potentially achieving this in just six months while alleviating upfront costs and
A flat illustration of a diagnostic test kit and reagent drop in a minimalist style.

May 21, 2026

Q-Line Biotech IPO Day 1: Issue subscribed over 2x, NIIs steal the show. Check GMP, issue details

The Q-Line Biotech IPO has made a significant impact on its opening day, with subscriptions exceeding two times the issue size, particularly driven by non-institutional investors (NIIs).Launched on May 21 and set to conclude on May 25, the IPO is priced between ₹326 and ₹343 per share, with a minimum bid for 400 shares. Q-Line Biotech, established in 2010, specializes in the development and distribution of diagnostic reagents, kits, and point-of-care devices, catering to healthcare needs through
A minimalist illustration of a lock and key symbolizing security and investment.

May 21, 2026

Visium Secures Strategic Funding from Top-Tier Investors and Unicorn Founders

Visium, a prominent player in the AI and data sector for regulated industries, has successfully completed its first institutional funding round, attracting support from top-tier investors and notable unicorn founders.Based in Lausanne, Switzerland, Visium has rapidly expanded since its inception in 2018, now employing 100 AI specialists and offering over 250 solutions to major clients in the life sciences sector, including Roche and Novartis. The recent funding round was co-led by Columbus Ventu
Minimalist illustration of an enzyme molecule and a laboratory flask on a dark background.

May 21, 2026

Manchester Imperagen raises €5.8 million Seed to scale AI and quantum-powered enzyme engineering

Imperagen, a biotech firm based in Manchester, has secured €5.8 million in Seed funding to enhance its AI and quantum-powered enzyme engineering capabilities. This investment aims to boost research and development, expand laboratory facilities, and strengthen market entry strategies over the next 18 months.The funding round was spearheaded by PXN Ventures, with contributions from existing investors like IQ Capital and Northern Gritstone, bringing the total capital raised by Imperagen to €9.8 mil